Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Omer Shvili who wrote (1346)	10/7/1998 7:21:00 PM
From: yosi s	Read Replies (2) \| Respond to of 1491

Comments on pars. from medical point of view today results were very positive. to get a quote from Dr Brian Andrews who chairs the section on neuro- trauma is very significant. As it shows what people in the know feels about the subject. Now we got to put this in perspective, Phase 2 is not getting approval from FDA. but here we have a few measurement that tells us that there is a fairly good chance of getting thru phase 3 with + results. After all, we did get some very pertinent results which are +; and they are very consistent. TThey make sense. It is unlikly that they are due to chance. Phase 3 is basically there to prove that this was no fluke. Decrease in intracranial pressure is statistically significant, this is very important. It shows that the drug is working like it suppose to . And in the severe cases, where it is easier to show that it works. It DOES. This is good enough for me. See Dr Fernandez comments. it is significant.... Also there are no issues with safety. in fact it is safer than placebo, as the blood presure is better with HU211. As for the stock price. we are in a bear market and expectation were for mortality differences to be wider, better headlines. Here I am disappointed as well. For had it happened, the news would have been better covered. How ever, the medical community took note of these events, as well as a possible partner. And in the long run that is what is importat. for that will bring us infront of FDA , and approval. Yosi